Limits...
Zeolite Nanoparticles for Selective Sorption of Plasma Proteins.

Rahimi M, Ng EP, Bakhtiari K, Vinciguerra M, Ali Ahmad H, Awala H, Mintova S, Daghighi M, Bakhshandeh Rostami F, de Vries M, Motazacker MM, Peppelenbosch MP, Mahmoudi M, Rezaee F - Sci Rep (2015)

Bottom Line: While the zeolite nanoparticles exposed to low plasma concentration (10%) exhibited a high selective adsorption for immunoglobulin gamma (i.e. IGHG1, IGHG2 and IGHG4) proteins.The zeolite nanoparticles can potentially be used for selectively capture of APOC-III in order to reduce the activation of lipoprotein lipase inhibition during hypertriglyceridemia treatment.The zeolite nanoparticles can be adapted to hemophilic patients (hemophilia A (F-VIII deficient) and hemophilia B (F-IX deficient)) with a risk of bleeding, and thus might be potentially used in combination with the existing therapy.

View Article: PubMed Central - PubMed

Affiliation: Faculty of Science, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

ABSTRACT
The affinity of zeolite nanoparticles (diameter of 8-12 nm) possessing high surface area and high pore volume towards human plasma proteins has been investigated. The protein composition (corona) of zeolite nanoparticles has been shown to be more dependent on the plasma protein concentrations and the type of zeolites than zeolite nanoparticles concentration. The number of proteins present in the corona of zeolite nanoparticles at 100% plasma (in vivo state) is less than with 10% plasma exposure. This could be due to a competition between the proteins to occupy the corona of the zeolite nanoparticles. Moreover, a high selective adsorption for apolipoprotein C-III (APOC-III) and fibrinogen on the zeolite nanoparticles at high plasma concentration (100%) was observed. While the zeolite nanoparticles exposed to low plasma concentration (10%) exhibited a high selective adsorption for immunoglobulin gamma (i.e. IGHG1, IGHG2 and IGHG4) proteins. The zeolite nanoparticles can potentially be used for selectively capture of APOC-III in order to reduce the activation of lipoprotein lipase inhibition during hypertriglyceridemia treatment. The zeolite nanoparticles can be adapted to hemophilic patients (hemophilia A (F-VIII deficient) and hemophilia B (F-IX deficient)) with a risk of bleeding, and thus might be potentially used in combination with the existing therapy.

No MeSH data available.


Related in: MedlinePlus

The effect of EMT- and FAU-zeolite nanoparticles on clotting time: prothrombin test (PT) is performed in pooled plasma with and without EMT- and FAU-zeolite nanoparticles (incubation for 30 min) in KC-10 coagulometer. Clotting time is expressed in seconds (Sec). Zeolite nanoparticles (0.1% and 0.4%) are incubated in 100 μl of 100% pooled plasma.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4663482&req=5

f7: The effect of EMT- and FAU-zeolite nanoparticles on clotting time: prothrombin test (PT) is performed in pooled plasma with and without EMT- and FAU-zeolite nanoparticles (incubation for 30 min) in KC-10 coagulometer. Clotting time is expressed in seconds (Sec). Zeolite nanoparticles (0.1% and 0.4%) are incubated in 100 μl of 100% pooled plasma.

Mentions: Fibrinogen is a glycoprotein that helps in the formation in blood clots. Since the fibrinogen has strong tendency to bind to both zeolite nanoparticles, thus it is very important to investigate their effect on clotting time. In respect to this, coagulometer was applied to determine prothrombin time (PT), i.e., a test that measures how long it takes the blood to clot. Without adding zeolite nanoparticles, the thrombin time is 23 sec (Figure 7). Upon treatment of 50% plasma for 30 min with 0.1% EMT- and FAU-zeolite nanoparticles, the clotting time is shortened with 5–7 seconds. One of the possibilities could be potentially due to the adsorption of fibrinogen to zeolite nanoparticles in the pooled plasma and hence, enhancing the rate of clot formation. The FAU-zeolite nanoparticles with higher surface area, higher total pore volume and higher surface charge density show clotting time of 18 sec, while for the EMT- zeolite nanoparticles is 16 sec. This indicates that EMT-zeolite nanoparticles with higher hydrophilicity (Si/Al ratio of 1.14) are more selectively in interacting with the fibrinogens and leads to enrichment of fibrinogens in blood, which is essential in blood clotting. Thus, these NPs accelerate the time of blood clot formation and the mechanism whereby these NPs accelerate coagulation remains to be elucidated.


Zeolite Nanoparticles for Selective Sorption of Plasma Proteins.

Rahimi M, Ng EP, Bakhtiari K, Vinciguerra M, Ali Ahmad H, Awala H, Mintova S, Daghighi M, Bakhshandeh Rostami F, de Vries M, Motazacker MM, Peppelenbosch MP, Mahmoudi M, Rezaee F - Sci Rep (2015)

The effect of EMT- and FAU-zeolite nanoparticles on clotting time: prothrombin test (PT) is performed in pooled plasma with and without EMT- and FAU-zeolite nanoparticles (incubation for 30 min) in KC-10 coagulometer. Clotting time is expressed in seconds (Sec). Zeolite nanoparticles (0.1% and 0.4%) are incubated in 100 μl of 100% pooled plasma.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4663482&req=5

f7: The effect of EMT- and FAU-zeolite nanoparticles on clotting time: prothrombin test (PT) is performed in pooled plasma with and without EMT- and FAU-zeolite nanoparticles (incubation for 30 min) in KC-10 coagulometer. Clotting time is expressed in seconds (Sec). Zeolite nanoparticles (0.1% and 0.4%) are incubated in 100 μl of 100% pooled plasma.
Mentions: Fibrinogen is a glycoprotein that helps in the formation in blood clots. Since the fibrinogen has strong tendency to bind to both zeolite nanoparticles, thus it is very important to investigate their effect on clotting time. In respect to this, coagulometer was applied to determine prothrombin time (PT), i.e., a test that measures how long it takes the blood to clot. Without adding zeolite nanoparticles, the thrombin time is 23 sec (Figure 7). Upon treatment of 50% plasma for 30 min with 0.1% EMT- and FAU-zeolite nanoparticles, the clotting time is shortened with 5–7 seconds. One of the possibilities could be potentially due to the adsorption of fibrinogen to zeolite nanoparticles in the pooled plasma and hence, enhancing the rate of clot formation. The FAU-zeolite nanoparticles with higher surface area, higher total pore volume and higher surface charge density show clotting time of 18 sec, while for the EMT- zeolite nanoparticles is 16 sec. This indicates that EMT-zeolite nanoparticles with higher hydrophilicity (Si/Al ratio of 1.14) are more selectively in interacting with the fibrinogens and leads to enrichment of fibrinogens in blood, which is essential in blood clotting. Thus, these NPs accelerate the time of blood clot formation and the mechanism whereby these NPs accelerate coagulation remains to be elucidated.

Bottom Line: While the zeolite nanoparticles exposed to low plasma concentration (10%) exhibited a high selective adsorption for immunoglobulin gamma (i.e. IGHG1, IGHG2 and IGHG4) proteins.The zeolite nanoparticles can potentially be used for selectively capture of APOC-III in order to reduce the activation of lipoprotein lipase inhibition during hypertriglyceridemia treatment.The zeolite nanoparticles can be adapted to hemophilic patients (hemophilia A (F-VIII deficient) and hemophilia B (F-IX deficient)) with a risk of bleeding, and thus might be potentially used in combination with the existing therapy.

View Article: PubMed Central - PubMed

Affiliation: Faculty of Science, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

ABSTRACT
The affinity of zeolite nanoparticles (diameter of 8-12 nm) possessing high surface area and high pore volume towards human plasma proteins has been investigated. The protein composition (corona) of zeolite nanoparticles has been shown to be more dependent on the plasma protein concentrations and the type of zeolites than zeolite nanoparticles concentration. The number of proteins present in the corona of zeolite nanoparticles at 100% plasma (in vivo state) is less than with 10% plasma exposure. This could be due to a competition between the proteins to occupy the corona of the zeolite nanoparticles. Moreover, a high selective adsorption for apolipoprotein C-III (APOC-III) and fibrinogen on the zeolite nanoparticles at high plasma concentration (100%) was observed. While the zeolite nanoparticles exposed to low plasma concentration (10%) exhibited a high selective adsorption for immunoglobulin gamma (i.e. IGHG1, IGHG2 and IGHG4) proteins. The zeolite nanoparticles can potentially be used for selectively capture of APOC-III in order to reduce the activation of lipoprotein lipase inhibition during hypertriglyceridemia treatment. The zeolite nanoparticles can be adapted to hemophilic patients (hemophilia A (F-VIII deficient) and hemophilia B (F-IX deficient)) with a risk of bleeding, and thus might be potentially used in combination with the existing therapy.

No MeSH data available.


Related in: MedlinePlus